| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥986.8B | ¥918.9B | +7.4% |
| Operating Income | ¥23.7B | ¥25.7B | -7.8% |
| Ordinary Income | ¥22.6B | ¥26.2B | -14.0% |
| Net Income | ¥10.4B | ¥14.7B | -29.3% |
| ROE | 6.1% | 9.0% | - |
Medical System Network Co., Ltd. reported FY2025 Q3 cumulative results with revenue of 98.68 billion yen (YoY +7.4%), operating income of 2.37 billion yen (YoY -7.8%), ordinary income of 2.26 billion yen (YoY -14.0%), and net income of 1.04 billion yen (YoY -29.3%). The company achieved top-line growth driven by expansion of pharmacy support services and contributions from new store openings, but profitability declined significantly due to rising personnel costs and decreased acute-illness patient visits, resulting in a revenue-up-profit-down pattern. The gross profit margin remained stable at 40.7%, but selling, general and administrative expenses of 37.79 billion yen compressed operating profit margin to 2.4%, down from 2.8% in the prior year period.
Revenue increased 6.79 billion yen (+7.4%) driven by three primary factors: pharmacy network member expansion (+9.6% to 11,769 locations), higher prescription unit prices (+5.0% due to high-value medications and longer-term prescriptions), and contributions from 17 new store openings during the period. The pharmacy support segment showed strong momentum with digital shift adoption reaching 6,549 stores (+12.5%) and pharmaceutical manufacturing/sales partnerships expanding to 8,560 stores (+30.4%).
Operating income declined 2.0 billion yen (-7.8%) as cost increases outpaced revenue growth. Key negative factors included rising personnel costs from wage increases implemented company-wide and a 2.3% decrease in same-store prescription volume due to reduced acute-illness patient visits. The operating margin compressed 0.4 percentage points to 2.4%, indicating limited operating leverage despite scale expansion.
The gap between ordinary income (2.26 billion yen) and net income (1.04 billion yen) widened significantly, reflecting an effective tax rate of approximately 49.6% and recognition of 145 million yen in impairment losses. The high tax burden substantially eroded bottom-line profitability. Additionally, the company temporarily suspended receivables securitization, resulting in trade receivables surging from 5.05 billion yen to 14.42 billion yen, which necessitated short-term borrowing increases from 5.88 billion yen to 10.87 billion yen to maintain liquidity.
Non-recurring factors include the 145 million yen impairment loss recognized during the period, which represents approximately 6.1% of operating income. The elevated effective tax rate also appears abnormal and warrants investigation as to whether it reflects temporary adjustments or structural issues.
This quarter exemplifies a revenue-up-profit-down pattern, where business expansion and service network growth drove top-line gains, but cost inflation and operational challenges eroded profitability across all income statement levels.
Regional Pharmacy Network Business (core business): Revenue of 94.85 billion yen (+8.0%), operating income of 4.33 billion yen (-2.1%). This segment accounts for approximately 96.1% of total revenue and represents the core business. Revenue growth was supported by contributions from stores opened in the prior period and a 5.0% increase in prescription unit prices reflecting higher-value medications and longer prescription periods. However, operating income declined 2.1% as same-store prescription volumes fell 2.3% due to decreased acute-illness patient visits and personnel cost increases compressed margins. The segment operating margin was approximately 4.6%, down from 5.0% in the prior year.
Rental, Equipment-Related, Meal Service, and Visiting Nursing Businesses: Revenue of 4.50 billion yen (-3.3%), operating income of 108 million yen (-37.2%). This segment represents approximately 4.6% of total revenue but experienced both revenue decline and sharp profit contraction. Management is implementing measures to address rising costs, raise profitability thresholds, and review unprofitable operations within this segment. The segment operating margin deteriorated to approximately 2.4% from 3.1% in the prior year.
The core Regional Pharmacy Network Business drove revenue growth but also contributed to profit decline, as cost increases in this largest segment overwhelmed the benefit of revenue expansion. The smaller segment's steeper profit decline (-37.2%) indicates more acute profitability challenges requiring structural adjustments. Overall, segment margin compression across both businesses underlies the company-wide profit decline despite continued revenue growth.
Profitability: ROE 5.9% (prior year 9.0%, -3.1pt), Operating Margin 2.4% (prior year 2.8%, -0.4pt), Net Profit Margin 1.0% (prior year 1.6%, -0.6pt). ROE deterioration reflects compressed profit margins and elevated tax burden, though financial leverage of 4.83x remains high. The 5.9% ROE falls below the company's historical range, indicating profitability challenges.
Efficiency: Asset Turnover 1.20x (sales/total assets), Receivables Turnover Period approximately 53 days (calculated from 14.42 billion yen receivables against quarterly sales), Inventory Turnover Period approximately 67 days. The receivables period extended significantly from approximately 20 days in the prior year due to temporary suspension of securitization, indicating working capital deterioration.
Financial Health: Equity Ratio 20.6% (prior year 23.0%, -2.4pt), Current Ratio 89.5% (below 100% threshold, indicating liquidity concern), Debt-to-Equity Ratio 3.83x (high leverage), Interest Coverage Ratio 10.0x (adequate debt service capacity).
Leverage: Total assets 82.32 billion yen (prior year 70.59 billion yen, +16.6%), Total equity 17.06 billion yen (prior year 16.34 billion yen, +4.4%), Financial Leverage 4.83x. Net debt position deteriorated as short-term borrowings surged while cash increased only modestly.
The company's financial metrics show deteriorating profitability (ROE, margins) and weakening liquidity (current ratio below 1.0x), while leverage remains elevated. The sharp increase in receivables and short-term debt indicates working capital strain requiring management attention.
Operating CF: Detailed cash flow data not disclosed in XBRL, but working capital deteriorated significantly with operating working capital negative 3.90 billion yen (versus positive 1.37 billion yen in prior year). Trade receivables surged 9.37 billion yen to 14.42 billion yen due to temporary suspension of receivables securitization, delaying cash collection timing. This working capital absorption likely resulted in negative or substantially reduced operating cash flow despite positive net income of 1.04 billion yen.
Investing CF: Specific investing cash flow not disclosed. The company opened 17 new pharmacy stores and attracted 17 medical institutions during the period (170% achievement of annual plan of 10 facilities), indicating active capital deployment in store development. Goodwill remains at 9.06 billion yen with 145 million yen impairment recognized, suggesting ongoing M&A activity and integration.
Financing CF: Short-term borrowings increased 10.32 billion yen to 10.87 billion yen, serving as a bridge financing source to offset the receivables increase from suspended securitization. Long-term debt decreased, indicating scheduled repayments. Dividend payments of 6.0 yen per share at mid-year were executed.
FCF: Not calculable from available data, but the combination of working capital deterioration and continued capital investment suggests constrained or negative free cash flow generation during the period.
Cash generation: Needs Monitoring. The temporary suspension of receivables securitization has created a structural working capital headwind requiring short-term debt financing, resulting in liquidity ratio compression to 89.5%. While management indicates this is timing-related rather than operational deterioration, the cash conversion cycle has meaningfully extended, and restoration of normal receivables management is critical to cash generation recovery.
Ordinary vs Net Income: The 1.2 billion yen gap (ordinary income 2.26 billion yen versus net income 1.04 billion yen) primarily reflects an abnormally high effective tax rate of approximately 49.6%. This elevated tax burden substantially exceeds typical corporate rates and suggests either significant unfavorable temporary differences, limitation of tax loss carryforwards, or other structural tax factors. The company should clarify whether this tax rate is recurring or temporary.
Non-recurring items: Impairment loss of 145 million yen was recognized during the period, representing approximately 6.1% of operating income or 14.4% of net income. While not individually material, this impairment indicates write-downs on certain assets or goodwill. Combined with the substantial goodwill balance of 9.06 billion yen (53.1% of equity), this raises monitoring requirements for future impairment risk.
Non-operating income composition: Net non-operating expense of 111 million yen (difference between operating income 2.37 billion yen and ordinary income 2.26 billion yen) includes interest expense of 237 million yen, resulting in an interest burden coefficient of 0.870. This interest cost reflects the company's high leverage but remains manageable given operating profit levels.
Accruals and cash quality: Operating working capital turned sharply negative at negative 3.90 billion yen (from positive 1.37 billion yen prior year), driven by receivables increase of 9.37 billion yen exceeding payables increase of 3.28 billion yen. This represents a significant red flag for earnings quality, as profit recognition significantly outpaced cash collection. The receivables surge is attributed to temporary suspension of securitization rather than credit quality deterioration, but the extended cash conversion cycle indicates earnings are not currently cash-backed.
Overall earnings quality is concerning due to the combination of low cash conversion (negative working capital change), elevated tax burden compressing net income, and presence of impairment charges. While the receivables issue is explained as timing-related, restoration of normal cash collection is essential to improve earnings quality.
Full-year guidance: Revenue 125.50 billion yen (+2.5% YoY), Operating Income 3.40 billion yen (+7.8% YoY), Ordinary Income 3.20 billion yen (+1.2% YoY), Net Income 1.30 billion yen (+3.0% YoY).
Progress rate vs full-year guidance (Q3 cumulative): Revenue 78.6% (98.68 billion yen / 125.50 billion yen), Operating Income 69.7% (2.37 billion yen / 3.40 billion yen), Ordinary Income 70.5% (2.26 billion yen / 3.20 billion yen), Net Income 80.0% (1.04 billion yen / 1.30 billion yen). Standard Q3 progress would be 75%, so revenue is tracking 3.6 percentage points ahead, while operating and ordinary income are approximately 5 percentage points behind plan. Net income progress of 80.0% appears ahead of schedule but reflects the elevated tax burden; on a pre-tax basis, progress is lagging.
Implied Q4 requirements: To achieve full-year guidance, Q4 requires revenue of 26.8 billion yen (versus Q3 quarterly average of 32.9 billion yen, suggesting seasonal softness or conservative guidance), operating income of 1.03 billion yen (versus Q3 quarterly average of 0.79 billion yen, requiring significant margin recovery), and net income of 0.26 billion yen (versus Q3 quarterly average of 0.35 billion yen).
Key assumptions for full-year guidance: Management forecasts pharmacy network membership reaching 12,000 locations (+231 from Q3), digital shift adoption of 6,850 stores (+301), pharmaceutical manufacturing/sales partnerships of 9,000 stores (+440), same-store prescription volume growth of +2.4% (versus -2.3% in Q3 cumulative, requiring significant turnaround), 25 new store openings for the full year (17 completed through Q3), and 10 medical facility attractions (17 already achieved, 170% of plan).
Guidance assessment: The full-year guidance implies substantial Q4 profit recovery despite soft revenue, requiring operating margin expansion to approximately 3.8% in Q4 versus 2.4% in Q3 cumulative. Management's assumptions include a meaningful reversal in same-store prescription trends from -2.3% to +2.4%, which appears optimistic without clear catalysts. The ahead-of-plan medical facility attractions and strong pharmacy network expansion provide positive indicators, but the cost structure challenges evident in Q3 create risk to the profit guidance. No upward or downward revisions were announced, suggesting management confidence in Q4 recovery, but execution risk remains elevated given current margin trends.
Dividend policy: Interim dividend of 6.0 yen per share paid, full-year forecast of 6.0 yen per share (representing annual total dividend; note that presentation materials reference 6.0 yen mid-year and 6.0 yen year-end, suggesting potential annual total of 12.0 yen, but XBRL data shows 6.0 yen annual forecast).
Payout ratio: Using XBRL forecast of 6.0 yen annual dividend against forecast EPS of 44.48 yen, the payout ratio is 13.5%. Using Q3 cumulative results of 1.04 billion yen net income (approximately 35.59 yen per share based on 29.23 million weighted average shares), mid-year dividend of 6.0 yen represents a payout ratio of approximately 16.9% on an annualized basis.
Dividend sustainability: The payout ratio of 13.5% to 16.9% (depending on interpretation) appears conservative and sustainable from a profit perspective. However, cash flow sustainability is uncertain given negative working capital generation and reliance on short-term borrowings during the period. The company holds cash of 20.14 billion yen against short-term debt of 10.87 billion yen, providing coverage, but free cash flow generation is constrained. Dividend payment of approximately 175 million yen (6.0 yen x 29.23 million shares for full year) represents a manageable absolute amount, but continued working capital strain could pressure cash availability.
Share buyback: No share buyback activity disclosed or announced during the period.
Capital allocation priorities: Management emphasizes profit generation and capital accumulation while implementing wage increases, indicating prioritization of employee investment and financial health rebuilding. The low payout ratio suggests capital retention for business investment and balance sheet strengthening given the elevated leverage (D/E 3.83x) and compressed equity ratio (20.6%).
Total shareholder return: Dividend-only strategy with no buybacks announced. The total return ratio equals the payout ratio of approximately 13.5% to 16.9%, which is conservative relative to earnings but appropriate given the financial health considerations and growth investment needs.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 5.9% vs. industry median 2.9% (2025-Q3, n=16 retail companies). The company's ROE exceeds the industry median by 3.0 percentage points, indicating above-average return on equity despite the year-over-year deterioration. Operating Margin 2.4% vs. industry median 3.9% (IQR: 1.2%-8.9%). The company's operating margin falls 1.5 percentage points below the industry median, placing it in the lower half of the distribution and indicating room for improvement in cost efficiency. Net Profit Margin 1.0% vs. industry median 2.2% (IQR: 0.2%-5.7%), positioning the company 1.2 percentage points below median, reflecting the compressed profitability from elevated tax burden and cost pressures.
Efficiency: Asset Turnover 1.20x vs. industry median 0.95x (IQR: 0.77-1.16), indicating the company achieves superior asset utilization, ranking in the upper quartile. This reflects the pharmacy network business model's relatively efficient asset conversion. Receivables Turnover Period approximately 53 days vs. industry median 30 days (IQR: 19-60 days), showing the company's receivables period extended above median due to the suspended securitization, though remaining within the interquartile range.
Financial Health: Equity Ratio 20.6% vs. industry median 56.8% (IQR: 39.2%-64.5%), placing the company significantly below the industry median by 36.2 percentage points, indicating substantially higher leverage relative to peers. Current Ratio 89.5% (0.895x) vs. industry median 1.93x (IQR: 1.48x-2.73x), showing the company's liquidity position is substantially weaker than industry standards, falling well below the 25th percentile and representing a notable financial health concern. Financial Leverage 4.83x vs. industry median 1.76x (IQR: 1.51-2.55), confirming the company employs significantly higher leverage than typical retail peers, nearly 3x the median level.
Growth: Revenue Growth YoY +7.4% vs. industry median +3.0% (IQR: -0.1%-9.2%), indicating the company's top-line growth exceeds the industry median and places in the upper half of the distribution, reflecting successful pharmacy network expansion.
Returns: Return on Assets 1.3% (calculated from net income 1.04B / average total assets 79.9B) vs. industry median 1.1% (IQR: 0.2%-4.2%), showing near-median performance.
Overall assessment: Medical System Network demonstrates above-median revenue growth and asset efficiency, but operates with significantly higher leverage and weaker liquidity compared to retail industry peers. Profitability margins are below industry median, indicating cost structure challenges despite superior asset turnover. The company's high leverage strategy amplifies ROE above industry median but creates elevated financial risk as evidenced by the below-standard equity ratio and current ratio.
Industry: Retail (16 companies), Comparison period: 2025-Q3, Source: Proprietary analysis
Liquidity and Refinancing Risk: Current ratio of 89.5% (0.895x) indicates current liabilities of 26.78 billion yen exceed current assets of 23.96 billion yen by 2.82 billion yen, creating a working capital deficit. Short-term borrowings surged to 10.87 billion yen (from 0.59 billion yen prior year), representing 40.6% of current liabilities and requiring refinancing within one year. Cash of 20.14 billion yen provides only 0.75x coverage of short-term debt plus near-term obligations, indicating maturity mismatch risk. The temporary suspension of receivables securitization has structurally weakened liquidity, and failure to restore normal cash collection or secure refinancing could constrain operations. This represents the most immediate and quantifiable financial risk.
Prescription Volume and Revenue Sustainability Risk: Same-store prescription volume declined 2.3% in Q3 cumulative due to decreased acute-illness patient visits, directly impacting the core pharmacy business that represents 96% of revenue. Management's full-year guidance assumes a reversal to +2.4% growth, requiring a swing of 4.7 percentage points without clear catalysts identified. If acute-illness patient visit patterns remain suppressed or prescription length continues extending, revenue growth could decelerate significantly. Each 1% change in same-store prescription volume impacts annual revenue by approximately 9.5 billion yen (based on existing store revenue base), creating meaningful earnings sensitivity.
Leverage and Impairment Risk: Debt-to-Equity ratio of 3.83x and equity ratio of 20.6% indicate highly leveraged capital structure with limited financial flexibility. Goodwill of 9.06 billion yen represents 53.1% of equity, and the company already recognized 145 million yen impairment loss during the period. If business performance deteriorates further (particularly margin compression continuing or prescription volume decline persisting), additional material goodwill impairment could occur, potentially eroding equity by an estimated 3-5 billion yen in a downside scenario, further compressing the equity ratio toward 15-17% levels and potentially triggering debt covenant concerns or credit rating pressure. The high effective tax rate of 49.6% also limits tax shield benefits from leverage, reducing the financial cushion.
Divergence between top-line growth and profitability trajectory: Medical System Network achieved 7.4% revenue growth driven by successful pharmacy network expansion (11,769 members, +9.6%) and strong partnerships in pharmaceutical manufacturing/sales (8,560 stores, +30.4%), demonstrating effective business model execution and market position strengthening. However, operating income declined 7.8% and net income fell 29.3%, with operating margin compressing from 2.8% to 2.4%, indicating that scale expansion is not translating to profitability improvement. The combination of 7.4% revenue growth and 2.4% operating margin yields an unfavorable "Rule of 40" metric of 9.8% (versus retail industry median of 5%), suggesting growth is being pursued at the expense of profitability. This earnings result highlights the critical challenge of achieving operating leverage and cost discipline while maintaining growth momentum.
Working capital management and cash flow quality require scrutiny: The temporary suspension of receivables securitization caused trade receivables to surge from 5.05 billion yen to 14.42 billion yen, necessitating short-term borrowing increases to 10.87 billion yen and compressing the current ratio to 89.5%, below the 1.0x safety threshold. While management characterizes this as a timing issue rather than credit quality deterioration, the extended cash conversion cycle represents a structural headwind until securitization resumes. Operating working capital turned negative 3.90 billion yen from positive 1.37 billion yen, indicating earnings are not currently cash-backed. The company's ability to restore normal receivables management and improve cash generation will be a critical determinant of financial flexibility and sustainable dividend capacity going forward. Investors should monitor Q4 and early FY2026 working capital normalization as a key indicator of financial health recovery.
Structural profitability improvement imperative ahead of next mid-term plan: With the next Medium-Term Management Plan scheduled for announcement in May 2026, the company faces pressure to demonstrate credible margin recovery and cost structure optimization. The 2.4% operating margin significantly lags the stated ambition embedded in the "Town Light Vision 2035" long-term framework, and management has emphasized cost control, unprofitable segment reviews, and profit accumulation as priorities. The full-year guidance implies Q4 operating margin recovery to approximately 3.8%, which would demonstrate early progress. However, structural headwinds including elevated personnel costs (from continued wage increases), acute-illness patient visit suppression, and high fixed cost base require systematic solutions beyond quarterly fluctuations. Successful execution of distribution efficiency improvements (consolidated delivery, regional inventory sharing) and pharmacy support business margin expansion will be critical to validating the long-term earnings growth story and supporting the current valuation multiples relative to retail peers.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
In Q3 FY March 2026, the company achieved higher net sales of 986.8百万円 (hundred million yen) year on year (+7.4%), but recorded a significant decline in earnings with operating profit at 23.7百万円 (-7.8%), ordinary income at 22.5百万円 (-14.0%), and net income at 10.1百万円 (-30.1%). Pharmacy support services continued to expand steadily, with 11,769 pharmaceutical network memberships (+9.6%), 6,549 Digital Shift installed stores (+12.5%), and 8,560 pharmaceutical manufacturing and marketing transaction outlets (+30.4%). Conversely, higher personnel expenses and a decrease in patients with acute illnesses (existing-store prescription volume -2.3%) weighed on profits. For the full year, the company forecasts net sales of 1,255.0百万円 and operating profit of 34.0百万円, implying earnings growth.
Pharmacy support segment continued to expand, with pharmaceutical network memberships at 11,769 (+9.6% YoY) and pharmaceutical manufacturing and marketing transaction outlets at 8,560 (+30.4% YoY). Community pharmacy segment posted revenue growth driven by contributions from stores opened in the prior year; average prescription unit price rose +5.0% on increased use of high-priced drugs and longer prescription durations. Accounts receivable surged to 144.22百万円 (from 50.53百万円 a year earlier), and the temporary suspension of receivables securitization led to an increase in short-term borrowings to 165.71百万円 (from 61.84百万円), lowering the equity ratio to 20.6%. 17 new community pharmacy openings and 17 medical institution attraction projects (substantially exceeding the annual plan of 10, achieving 170.0%) indicate steady development activity. While net sales remained on an upward trajectory, higher SG&A pushed the operating margin down to 2.4% (from 2.8% a year earlier), highlighting cost management as a key issue.
For the full year ending March 2026, the company projects net sales of 1,255.0百万円 (+2.5% YoY), operating profit of 34.0百万円 (+7.8%), ordinary income of 32.0百万円 (+1.2%), and net income of 13.0百万円 (+3.0%). The outlook assumes expansion in the pharmacy support segment (pharmaceutical network 12,000, Digital Shift 6,850 stores) and existing-store prescription volume +2.4% versus the prior year. The company plans 25 new store openings and 10 medical institution attraction projects, and expects to expand counterparties in the pharmaceutical manufacturing and marketing, and logistics segments.
In FY2026, while implementing wage increases, the company will emphasize strict cost control, profit retention, and capital build-up. In community pharmacies, it will drive productivity improvement in existing stores, focus on medical mall-centered store development, and ensure appropriate cost management. In the pharmacy support segment, it will promote distribution improvements (one delivery per weekday, elimination of Saturday deliveries, fewer rush deliveries), service enhancement, and construction of area networks. Company-wide, it will review unprofitable segments and improve profitability, and is formulating the next medium-term management plan (to be announced in May 2026) based on the long-term vision “Machino Akari Vision 2035.”
Foster a medical mindset and deliver high-quality pharmacotherapy: target existing-store prescription volume +2.4% YoY; focus on medical mall-centered store development (25 new stores, 10 attraction projects). Expand the pharmacy support segment: targets of pharmaceutical network 12,000 (+997), Digital Shift 6,850 stores (+830), pharmaceutical manufacturing and marketing 9,000 stores (+1,819), and pharmaceutical logistics 3,700 stores (+2,128). Improve and streamline distribution: promote one delivery per weekday, no Saturday deliveries, reduction of rush deliveries, and construction of area networks (establish a shared inventory framework). DX strategy: leverage advanced technologies to improve access to healthcare, enhance the quality of pharmaceutical care, streamline operations, and elevate management quality. Financial strategy: pursue investments with a focus on capital efficiency and shareholder value, enforce cost control, and prioritize profit retention and capital build-up.
Risk that existing-store prescription volume falls below the prior year due to fewer patients with acute illnesses and longer prescription durations (actual existing-store prescription volume -2.3%). Risk of operating margin compression as rising personnel expenses (due to wage hikes) lift SG&A. Liquidity risk materialized as the temporary suspension of receivables securitization delayed collection timing, resulting in negative operating CF and a sharp increase in short-term borrowings. Credit risk and constraints on financial flexibility due to high leverage (D/E ratio 3.83x, Debt/Capital 61.1%) and a decline in the equity ratio to 20.6%. Impairment risk on goodwill of 90.57百万円 (53.1% of net assets); an impairment loss of 1.45百万円 has already been recognized.